ARWR Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Company profile
Ticker
ARWR
Exchange
Website
CEO
Christopher Anzalone
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
SEC CIK
Corporate docs
IRS number
460408024
ARWR stock data
()
News
Arrowhead Announces ARO-DUX4 As First Muscle Targeted RNAi Candidate Using TRiMTM Platform
15 Apr 21
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
1 Mar 21
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
11 Feb 21
Stocks That Hit 52-Week Highs On Wednesday
10 Feb 21
B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $106
8 Feb 21
Press releases
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
16 Apr 21
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
15 Apr 21
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
1 Mar 21
Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
4 Feb 21
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
4 Feb 21
Investment data
Securities sold
Number of investors
Calendar
4 Feb 21
19 Apr 21
30 Sep 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Sep 20 | Sep 19 | Sep 18 | Sep 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 139.92M | 139.92M | 139.92M | 139.92M | 139.92M | 139.92M |
Cash burn (monthly) | 1.22M | 26.76M | 8.02M | 9.36M | 12.97M | 9.23M |
Cash used (since last report) | 4.42M | 96.86M | 29.02M | 33.89M | 46.96M | 33.42M |
Cash remaining | 135.5M | 43.06M | 110.9M | 106.03M | 92.96M | 106.5M |
Runway (months of cash) | 111.0 | 1.6 | 13.8 | 11.3 | 7.2 | 11.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 21 | Given Douglas B | Common Stock | Sell | Dispose S | Yes | No | 88.73 | 1,125 | 99.82K | 13,875 |
8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 89.66 | 5,436 | 487.39K | 293,375 |
8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 88.88 | 45,348 | 4.03M | 298,811 |
8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 88.08 | 31,255 | 2.75M | 344,159 |
8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 86.72 | 7,961 | 690.38K | 375,414 |
8 Feb 21 | Patrick O'Brien | Common Stock | Option exercise | Aquire M | No | No | 5.22 | 90,000 | 469.8K | 383,375 |
8 Feb 21 | Patrick O'Brien | Stock Option Common Stock | Option exercise | Dispose M | No | No | 5.22 | 90,000 | 469.8K | 60,000 |
15 Jan 21 | Given Douglas B | Common Stock | Sell | Dispose S | Yes | No | 83.28 | 3,000 | 249.84K | 12,500 |
14 Jan 21 | James C Hamilton | Common Stock | Sell | Dispose S | No | No | 81.82 | 3,814 | 312.06K | 126,250 |
14 Jan 21 | James C Hamilton | Common Stock | Sell | Dispose S | No | No | 80.97 | 6,186 | 500.88K | 130,064 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
66.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 311 |
Opened positions | 72 |
Closed positions | 24 |
Increased positions | 90 |
Reduced positions | 110 |
13F shares |
Current |
---|---|
Total value | 5.41B |
Total shares | 69.39M |
Total puts | 737K |
Total calls | 1.33M |
Total put/call ratio | 0.6 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 12.56M | $963.97M |
Vanguard | 9.28M | $712.17M |
STT State Street | 3.93M | $301.7M |
Johnson & Johnson Innovation - JJDC | 3.26M | $250.21M |
IVZ Invesco | 3.26M | $250.05M |
JPM JPMorgan Chase & Co. | 2.41M | $184.89M |
Geode Capital Management | 1.61M | $123.4M |
NTRS Northern Trust | 1.56M | $119.58M |
CS Credit Suisse | 1.51M | $116.17M |
FMR | 1.42M | $108.95M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
add, added, agency, AHA, arrangement, backed, cloud, computing, Customer, exacerbated, expansion, Finally, hosted, interim, lead, leader, line, maturity, mutual, Olpasiran, owed, Park, prepaid, profit, project, rare, Realized, reinvested, separately, Session, Software, strategy, structure, Subtopic, Takeda, toxicity, University, webinar, worsening
Removed:
adaptive, advancement, advisory, aggregate, apparent, applying, approach, approval, assessed, base, begin, borrow, borrowing, carrying, classification, collateralized, collectively, critical, CTA, curative, deducting, determinable, determining, developing, diluted, discontinuation, discounted, dual, effect, efficacy, employed, entity, evaluate, excluded, executed, experience, expired, extend, FDA, filed, finance, greater, grown, histological, implicit, incremental, IND, index, industry, Jersey, leased, lessor, meet, merit, minimum, moved, NDA, nominated, obtain, obtaining, occasion, oral, ownership, package, pattern, permitted, pilot, pivotal, potentially, practical, prepare, public, reaching, readily, recognize, registration, requiring, response, Roche, scale, selected, serve, supported, typically, variation, vary, virtually, vivo, volume
Financial reports
10-Q
2021 Q1
Quarterly report
4 Feb 21
10-K
2020 FY
Annual report
23 Nov 20
10-Q
2020 Q3
Quarterly report
5 Aug 20
10-Q
2020 Q2
Quarterly report
7 May 20
10-Q
2020 Q1
Quarterly report
5 Feb 20
10-K
2019 FY
Annual report
25 Nov 19
10-Q
2019 Q3
Quarterly report
5 Aug 19
10-Q
2019 Q2
Quarterly report
8 May 19
10-Q
2019 Q1
Quarterly report
7 Feb 19
10-K
2018 FY
Annual report
11 Dec 18
Current reports
8-K
Departure of Directors or Certain Officers
24 Mar 21
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
4 Feb 21
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
23 Nov 20
8-K
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
9 Oct 20
8-K
Departure of Directors or Certain Officers
8 Sep 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
5 Aug 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
7 May 20
8-K
Departure of Directors or Certain Officers
1 May 20
8-K
Entry into a Material Definitive Agreement
19 Mar 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
5 Feb 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
5 Aug 20
S-8
Registration of securities for employees
22 May 20
424B5
Prospectus supplement for primary offering
4 Dec 19
424B5
Prospectus supplement for primary offering
2 Dec 19
S-3ASR
Automatic shelf registration
2 Dec 19
S-8
Registration of securities for employees
29 Mar 19
S-3ASR
Automatic shelf registration
29 Nov 18
S-8
Registration of securities for employees
21 Mar 18
424B5
Prospectus supplement for primary offering
18 Jan 18
424B5
Prospectus supplement for primary offering
16 Jan 18
Proxies
DEF 14A
Definitive proxy
27 Jan 21
DEF 14A
Definitive proxy
28 Jan 20
PRE 14A
Preliminary proxy
14 Jan 20
DEFA14A
Additional proxy soliciting materials
25 Jan 19
DEF 14A
Definitive proxy
25 Jan 19
DEF 14A
Definitive proxy
24 Jan 18
DEFA14A
Additional proxy soliciting materials
24 Jan 18
DEF 14A
Definitive proxy
31 Jan 17
DEFA14A
Additional proxy soliciting materials
31 Jan 17
DEF 14A
Definitive proxy
18 Jan 16
Other
UPLOAD
Letter from SEC
7 Mar 21
CORRESP
Correspondence with SEC
4 Feb 21
UPLOAD
Letter from SEC
26 Jan 21
CT ORDER
Confidential treatment order
18 Mar 19
EFFECT
Notice of effectiveness
2 Feb 17
EFFECT
Notice of effectiveness
2 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
CORRESP
Correspondence with SEC
31 Jan 17
CORRESP
Correspondence with SEC
18 Jan 17
CORRESP
Correspondence with SEC
18 Jan 17
Ownership
4
ARROWHEAD PHARMACEUTICALS / DOUGLAS B GIVEN ownership change
24 Feb 21
4
ARROWHEAD PHARMACEUTICALS / Patrick O'Brien ownership change
10 Feb 21
SC 13G/A
ARROWHEAD PHARMACEUTICALS / VANGUARD ownership change
10 Feb 21
SC 13G/A
ARROWHEAD PHARMACEUTICALS / BlackRock ownership change
26 Jan 21
4
ARROWHEAD PHARMACEUTICALS / DOUGLAS B GIVEN ownership change
19 Jan 21
4
ARROWHEAD PHARMACEUTICALS / James C Hamilton ownership change
15 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
12 Jan 21
4
ARROWHEAD PHARMACEUTICALS / James Hassard ownership change
8 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Patrick O'Brien ownership change
7 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
7 Jan 21
Patents
APP
Utility
Rnai Agents for Hepatitis B Virus Infection
8 Apr 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
APP
Utility
Integrin Targeting Ligands and Uses Thereof
1 Apr 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
APP
Utility
Integrin Targeting Ligands and Uses Thereof
11 Mar 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
APP
Utility
Rnai Therapy for Hepatitis B Virus Infection
25 Feb 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
GRANT
Utility
Compositions and methods for inhibiting gene expression of Hif2alpha
23 Feb 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
Transcripts
2021 Q1
Earnings call transcript
5 Feb 21
2020 Q4
Earnings call transcript
23 Nov 20
2020 Q3
Earnings call transcript
5 Aug 20
2020 Q2
Earnings call transcript
8 May 20
2020 Q1
Earnings call transcript
5 Feb 20
2019 Q4
Earnings call transcript
26 Nov 19
2019 Q3
Earnings call transcript
5 Aug 19
2019 Q2
Earnings call transcript
8 May 19
2019 Q1
Earnings call transcript
8 Feb 19
2018 Q4
Earnings call transcript
11 Dec 18
Reddit threads
ARKX will be listed on Tuesday, March 30 2021
28 Mar 21
$PLTR Alex Karp Interview: FULL BREAKDOWN 3/16
16 Mar 21
Lengthy DD on $PHIO: 200% upside and short squeeze candidate
10 Mar 21
Any promising pharma stock in a mid-long term horizon?
3 Mar 21
To all ARKG holders out there
3 Mar 21
Good examples of former penny stocks that are consistently at $20+ today?
22 Feb 21
I took a look at 140 biotech companies. These are the five I like:
9 Feb 21
Daily Discussion Thread - February 4th, 2021
4 Feb 21
$ATOS - Short DD
1 Feb 21
Daily Discussion Thread - November 23rd, 2020
23 Nov 20